Sickle Cell Disease News Home | Sickle Cell Disease News
WEB3 days ago · Becoming educated and informed about sickle cell disease is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes. Get informed
Bluebird set for Lyfgenia’s launch after ‘remarkable’ approvals
WEBDec 21, 2023 · Bluebird Bio’s Lyfgenia (lovotibeglogene autotemcel) — formerly lovo-cel — was cleared for SCD patients, ages 12 and older, with a history of vaso-occlusive events (VOEs). It was approved along with Casgevy (exagamglogene autotemcel), or exa-cel, from Vertex Pharmaceuticals and CRISPR Therapeutics. “To …
Advocates for Sickle Cell Disease Hope to Enlighten the Public
WEBAug 30, 2022 · This September’s National Sickle Cell Disease Awareness Month seeks to highlight the scale of the disease while bringing communities together to help patients, families, and friends across generations who are affected by the disease.
FDA approves lovo-cel, now Lyfgenia, for sickle cell disease
WEBDec 8, 2023 · The U.S. Food and Drug Administration (FDA) has approved lovotibeglogene autotemcel, a gene therapy from Bluebird Bio known as lovo-cel, for treating sickle cell disease (SCD) patients ages 12 and older who have a history of vaso-occlusive events (VOEs), including painful vaso-occlusive crises (VOCs), acute …
Supporters gearing up to raise awareness for SCD in September
WEBAug 31, 2023 · Advocates, patients, caregivers, doctors and others impacted by sickle cell disease (SCD) are gathering in September to bring attention to the struggles and needs of those living with the condition, and the importance of research and developing treatments.
About Us – Sickle Cell Disease News
WEBSickle Cell Disease News is a digital platform intended to provide the sickle cell disease (SCD) community with the most recent news and information on SCD, as well as first-hand community perspectives from our patient and caregiver columnists.
FDA approves Casgevy, 1st CRISPR therapy for sickle cell disease
WEBDec 8, 2023 · The U.S. Food and Drug Administration (FDA) has approved the gene-editing therapy exagamglogene autotemcel (exa-cel) — now known as Casgevy — for treating sickle cell disease (SCD).
Etavopivat for sickle cell disease | Sickle Cell Disease News
WEBJun 29, 2024 · A Phase 1/2 clinical trial (NCT06198712) is testing the safety and efficacy of etavopivat in up to 50 adolescents with SCD, ages 12-18. Patients will take etavopivat as tablets once daily for 96 weeks, or nearly two years. The last visit will take place four weeks after the end of treatment.
Osivelotor for sickle cell disease | Sickle Cell Disease News
WEBMay 29, 2024 · Osivelotor, previously known as PF-07940367, GBT601, or GBT021601, is an investigational oral therapy being evaluated as a possible treatment for sickle cell disease (SCD). It’s being developed by Pfizer, which acquired osivelotor’s original developer, Global Blood Therapeutics, in a 2022 deal.
Taking a holistic approach to sickle cell disease management
WEBJul 3, 2023 · It’s also about incorporating a holistic approach into my sickle cell management plan. This involves considering the disease’s physical, emotional, and social aspects. While medical interventions are essential for pain management, integrating holistic strategies has changed my life.